Stenty s lekarstvennym pokrytiem: voprosy bezopasnosti v otdalennom periode


Cite item

Full Text

Abstract

В основе подавляющего большинства случаев ишемической болезни сердца (ИБС)лежит стенозирующее атеросклеротическое поражение коронарных артерий. У значительной части больных проведение только медикаментозной терапии не приводит к оптимальному результату, что заставляет прибегать к инвазивным методам лечения, которые механически восстанавливают нормальный коронарный кровоток. Во всем мире количество выполняемых чрескожных вмешательств (ЧКВ) увеличивается с каждым годом, главным образом с применением стентов с лекарственным покрытием (СЛП). Постепенное вытеснение непокрытых металлических стентов (НМС) и замена их на СЛП привели к значительному снижению частоты развития внутристентового рестеноза и соответственно потребности в проведении повторного ЧКВ. Однако после публикации в 2006г. результатов исследования BASKET - LATE и метаанализа E.Camenzind появились сомнения в безопасности СЛП в отдаленном периоде.

About the authors

Yu. A Karpov

ФГУ РКНПК Росмедтехнологий, Москва

A. N Samko

ФГУ РКНПК Росмедтехнологий, Москва

V. V Buza

ФГУ РКНПК Росмедтехнологий, Москва

References

  1. Pfisterer M, Brunner-La Rocca H.P., Buser P.T. et al. BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug - eluting stents: an observational study of drug - eluting versus bare - metal stents. J Am Coll Cardiol. 2006; 48(12): 2584–9.
  2. Camenzind E, Steg P.G., Wijns W. A metaanalysis of first generation drug eluting stent programs. Circulation 2007; 115: 1440–5.
  3. Cutlip D.E., Windecker S, Mehran R et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344–51.
  4. Werkum, J.W., de Korte F.I., Heestermans A.A. et al. High recurrence rates after a first episode of stent thrombosis: Results from the Dutch Stent Thrombosis Study. American College of Cardiology Scientific Sessions/i2 Summit - SCAI Annual Meeting; March 29, 2008;
  5. Chicago, I.L. Nakazawa G, Finn A.V., Virmani R. Drugeluting stent pathology - should we still be cautious? Nat Clin Pract Cardiovasc Med 2008; 5(1): 1–3.
  6. Awata M, Kotani J, Uematsu M. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus - eluting stent implantation: comparison with bare - metal stents. Circulation 2007; 116(8): 910–6..
  7. Togni M, Ra ber L, Cocchia R et al. Local vascular dysfunction after coronary paclitaxel - eluting stent implantation. Int J Cardiol 2007; 120(2): 212–20.
  8. Virmani R, Guagliumi G, Farb A et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus - eluting stent: should we be cautious? Circulation 2004; 109: 701–5.
  9. Nebeker J.R., Virmani R, Bennett C.L. et al. Hypersensitivity cases associated with drugeluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006; 47(1): 175–81.
  10. Zhang F, Qian J, Ge J. Very late stent thrombosis in late stent malapposition after sirolimus - eluting stent implantation. Int Heart J. 2007; 48(5): 591–6.
  11. Steffel J, Latini R.A., Akhmedov A. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug - eluting stent design. Circulation. 2005; 112(13): 2002–11.
  12. Stone G.W., Moses J.W., Ellis S.G. et al. Safety and efficacy of sirolimusand paclitaxel - eluting coronary stents. N Engl J Med 2007; 356: 998–1008.
  13. Spaulding C, Daemen J, Boersma E et al. A pooled analysis of data comparing sirolimuseluting stents with bare - metal stents. N Engl J Med 2007; 356: 989–97.
  14. Mauri L, Hsieh W.H., Massaro J.M. et al. Stent thrombosis in randomized clinical trials of drug - eluting stents. N Engl J Med 2007; 356(10): 1020–9.
  15. Nordmann A.J., Briel M, Bucher H.C. Mortality in randomized controlled trials comparing drug - eluting vs. bare metal stents in coronary artery disease: a meta - analysis. Eur Heart J 2006 Dec; 27(23): 2784–814.
  16. Stettler C, Wandel S, Allemann S et al. Outcomes associated with drug - eluting and baremetal stents: a collaborative network metaanalysis. Lancet. 2007; 370(9591): 937–48.
  17. Daemen J, Ong A.T., Stefanini G.G. et al. Three - year clinical follow - up of the unrestricted use of sirolimus - eluting stents as part of the Rapamycin - Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Am J Cardiol. 2006; 98(7): 895–901.
  18. de la Torre-Herna´ndez J.M., Alfonso F, Herna´ndez F et al. ESTROFA Study Group.Drug - eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpan~ ol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol 2008; 51(10): 986–90.
  19. Tu J.V., Bowen J, Chiu M et al. Effectiveness and safety of drug - eluting stents in Ontario. N Engl J Med. 2007; 357(14): 1393–402.
  20. Steg G. Patients face more than fourfold higher risk of death than bare - metal - stenttreated patients oral presentation at the European Society of Cardiology Congress 2007.
  21. Jensen L.O., Maeng M, Kaltoft A et al. Stent thrombosis, myocardial infarction, and death after drug - eluting and bare - metal stent coronary interventions. J Am Coll Cardiol. 2007; 50(5): 463–70.
  22. Lagerqvist B, James S.K., Stenestrand U et al. Long - term outcomes with drug - eluting stents versus bare - metal stents in Sweden. N Engl J Med 2007; 356: 1009–19.
  23. Williams D.O., Abbott J.D., Kip K.E. DEScover Investigators.Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug - eluting stents: report of the DEScover Registry. Circulation. 2006; 114(20): 2154–62.
  24. Abbott J.D., Voss M.R., Nakamura M et al. Unrestricted use of drug - eluting stents compared with bare - metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol 2007; 50(21): 2029–36.

Copyright (c) 2009 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies